本文讨论了2022年1月1日至2022年6月30日期间发表的关于高级别胶质瘤放射治疗的研究，特别关注其分子生物学基础。重点在于放射治疗的耐药性、放射增敏和毒副作用的进展。在2022年上半年，我们在理解高级别胶质瘤耐药机制方面取得了几项重要进展。此外，在前期和临床环境中，针对这些致命肿瘤的几种放射增敏程序的发展也在进展中，包括小分子放射增敏剂研究、新的分段协议和新的免疫刺激剂，这反映出本领域的疯狂研究努力。然而，自2005年以来，我们的研究努力未能对高级别胶质瘤的治疗指南产生显著改进。本文讨论了这一僵局的可能原因及克服措施。版权所有 © 2023 Elsevier B.V.。保留所有权利。

This article discusses the studies on radiotherapy of high-grade gliomas published between January 1, 2022, and June 30, 2022, with special reference to their molecular biology basis. The focus was on advances in radioresistance, radiosensitization and the toxicity of radiotherapy treatments. In the first half of 2022, several important advances have been made in understanding resistance mechanisms in high-grade gliomas. Furthermore, the development of several radiosensitization procedures for these deadly tumors, including studies with small molecule radiosensitizers, new fractionation protocols, and new immunostimulatory agents, has progressed in both the preclinical and clinical settings, reflecting the frantic research effort in the field. However, since 2005 our research efforts fail to produce significant improvements to treatment guidelines for high-grade gliomas. Possible reasons for this stalemate and measures to overcome it are discussed.Copyright © 2023 Elsevier B.V. All rights reserved.